Co-Diagnostics, Inc. (Co-Dx)

Co-Diagnostics, Inc. (Co-Dx)

Co-Diagnostics, Inc. (Co-Dx) develops, manufactures, markets and licenses state-of-the-art PCR diagnostics solutions using its patented Co-Primers® technology. Founded in 2013 and publicly traded since 2017, Co-Dx moved quickly early in the pandemic, leveraging its proprietary design platform technology to become the first US-based company to have a CE-marking for a COVID-19 test. Since that time, Co-Dx has sold over 35 million COVID-19 tests to centralized labs in around 50 countries, including the US after receiving an FDA EUA. Driven by its mission to improve the quality of global health by increasing access to robust, high-quality, affordable PCR, Co-Dx is preparing to launch the Co-Dx PCR Pro™. This innovative at-home and POC real-time PCR infectious disease testing instrument and platform are designed to make the advantages of gold-standard real-time PCR accessible in the home or at the POC, allowing fast, affordable PCR test results anytime, anywhere.

Infectious Disease Testing, Molecular Diagnostics, Multiplex Testing, Point of Care Testing

Yes

Direct Sales, Distributor/Agent/Representative, Investor

Co-Dx Diagnostics Solutions (Logix Smart, PCR Pro, Vector Control Solutions)